Impact of Chemical Peels and Fractional Laser on IGF-1 Levels in Skin
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- IGF-1 Levels
研究概览
简要总结
The purpose of this study is to evaluate the impact of fractional laser versus chemical peels on IGF-1 levels in skin.
详细描述
This study is designed to assess the feasibility of using a fractional non ablative laser and chemical peels to wound skin, and thereby elicit a change in IGF-1. Our hypothesis is that fractional non ablative laser and a TCA chemical peel can induce similar effects as the fractional ablative laser at three months. In other words, our theory is that these approaches can stimulate the production of IGF-1 in older skin and restore UV damage repair and response mechanisms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects >55 years old
- •Fitzpatrick type I-II
- •Able to provide informed consent.
- •Cutaneous photodamage of 3 or above on the Larnier photodamage scale (see Appendix).
排除标准
- •Prior laser or peel treatment in the area evaluated in the current study in the past year.
- •Currently taking immunosuppressant medications known to interfere wound healing or anti-inflammatory medications (such as NSAIDs, or steroids).
- •Subjects who have underlying diseases that could alter wound healing response (such as Diabetes).
- •Currently taking insulin.
- •History of substance abuse, mental dysfunction, or other factors limiting ability to cooperate with study.
- •History of abnormal scarring such as Keloids.
- •History of vitiligo.
- •Allergy or sensitivity or allergy to topical anesthesia
- •Inability to use sunscreen.
- •History of smoking in the last 10 years
- •Scar or prior surgery in the area of treatment.
- •Use of isotretinoin in the prior 6 months
- •Subjects who have bleeding disorders or who are taking anticoagulants
结局指标
主要结局
IGF-1 Levels
时间窗: 3 months
To quantify IGF-1 levels in skin
次要结局
未报告次要终点
研究者
Molly A. Wanner, MD
Dermatologist
Massachusetts General Hospital
